Company intelligence / Profile preview

Beijing Kexin Jurun Pharmaceutical Technology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Kexin Jurun Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative small molecule therapies for metabolic diseases. The company's primary focus is on addressing prevalent conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Their lead programs include novel GLP-1 receptor agonists and SGLT2 inhibitors designed to improve glycemic control and weight management. By leveraging advanced medicinal chemistry, Beijing Kexin Jurun aims to provide more effective and safer treatment options for patients with metabolic disorders.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Beijing Kexin Jurun Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Kexin Jurun Pharmaceutical Technology.

Explore the full profile